PharmaShots | Incisive News in 3 Shots

Subscribe Now

GSK

GSK’s Arexvy Receives EC’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years

GSK’s Arexvy Receives EC’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years

June 7, 2023

GSK Reports the US FDA Acceptance of sBLA for Jemperli (dostarlimab) to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK Reports the US FDA Acceptance of sBLA for Jemperli (dostarlimab) to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial...

June 6, 2023

GSK Presents Results of 5-in-1 Meningococcal ABCWY Vaccine Candidate at ESPID 2023

GSK Presents Results of 5-in-1 Meningococcal ABCWY Vaccine Candidate at ESPID 2023

May 16, 2023

GSK’s Arexvy Receives the US FDA’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years

GSK’s Arexvy Receives the US FDA’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years

May 5, 2023

GSK Reports EMA’s Validation of MAA for Jemperli (dostarlimab) to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK Reports EMA’s Validation of MAA for Jemperli (dostarlimab) to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cance...

April 25, 2023

GSK to Acquire BELLUS Health for ~$2.0B

GSK to Acquire BELLUS Health for ~$2.0B

April 18, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us